A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naive Subjects With Type 2 Diabetes.
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Repaglinide (Primary) ; Gliclazide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.